Related Experiment Video
Updated: Nov 26, 2025
06:51
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15.6K
Recent updates for antibody therapy for acute lymphoblastic leukemia
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China.
Experimental Hematology & Oncology
|December 9, 2020
Summary
Antibody-based therapies show promise for acute lymphoblastic leukemia (ALL), especially in adults where outcomes lag. Antibody-drug conjugates and bispecific antibodies offer improved remission rates and survival, guiding future treatment strategies.
Area of Science:
- Hematologic Malignancies
- Immunotherapy
- Oncology
Background:
- Acute lymphoblastic leukemia (ALL) has high cure rates in children but suboptimal outcomes in adults.
- Conventional chemotherapy faces limitations in adult ALL treatment.
- Antibody-based therapies offer novel mechanisms for ALL treatment.
Purpose of the Study:
- To review milestones in antibody-based therapies for ALL.
- To discuss the role of antibody drugs in ALL treatment strategies.
- To explore combinations of antibody therapy with standard care.
Main Methods:
- Review of antibody-drug conjugates (ADCs) like inotuzumab ozogamicin.
- Analysis of bispecific antibodies (BsAbs) such as blinatumomab.
- Examination of clinical development and combinational strategies.
Main Results:
- Inotuzumab ozogamicin showed an 81% complete remission rate in R/R CD22+ ALL.
- Blinatumomab achieved a 44% complete response rate and 7.7 months median survival.
- Blinatumomab led to complete MRD response in 80% of achieving complete remission patients.
Conclusions:
- Antibody-based therapies demonstrate significant promise for ALL treatment.
- Integrating antibody drugs into ALL treatment requires further research.
- Combinational strategies with chemotherapy, CAR T-cell therapy, and HSCT are key challenges.
Related Concept Videos
01:31Hybridoma Technology
16.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
16.6K
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:26Antibody Actions
1.9K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.9K
01:24B Cell Activation and Differentiation
15.3K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.3K
01:27Tumor Immunotherapy
888
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
888
01:36Humoral Immune Responses
80.9K
Overview
80.9K